Healthcare
Live Price
Offline$0.60
-14.27% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ASLAN Pharmaceuticals Limited (ASLN) is a Healthcare stock with a market cap of $777.12M. The stock last traded around $0.60. Baseline metrics include revenue growth of 0.0%, EPS growth of +26.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.9%, free cash flow -20.7% with operating margin -364.5% and ROIC -323.1%. Valuation already assumes a fairly strong business story at price/sales 64.8. Stock Foundry combines ASLN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ASLN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ASLN Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ASLN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.0M
FY Net Income
-$47.1M
-162.8% YoY
Free Cash Flow
-$25.8M
-71.4% YoY
Revenue Growth
+0.0%
EPS Growth
+26.9%
Gross Margin
97.1%
Net Margin
-368.5%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 12M | 0 | 0 | 0 | 3M |
| Gross Profit | 12M | -332K | -282K | -298K | 3M |
| Operating Income | -44M | -48M | -34M | -16M | -46M |
| EBITDA | -39M | -47M | -29M | -15M | -45M |
| Net Income | -44M | -51M | -35M | -18M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 57M | 90M | 14M | 22M |
| Total Assets | 25M | 61M | 95M | 16M | 23M |
| Total Liabilities | 38M | 53M | 37M | 26M | 24M |
| Shareholder Equity | -13M | 8M | 57M | -10M | -2M |
| Total Debt | 27M | 38M | 31M | 19M | 18M |
| Net Debt | 6M | -19M | -59M | 5M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
26M
-71.4% YoY
Capital Expenditures
3K
+40.8% YoY
Free Cash Flow
26M
-71.4% YoY
Key ratios
Gross Margin
97.1%
Operating Margin
-364.5%
Net Margin
-368.5%
ROE
1796.9%
Debt / Equity
-2.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.